| Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics) CV Cruz, JA Watson, I Molina Romero, NJ White Wellcome Open Research 9, 342, 2024 | | 2024 |
| Death from diphtheria NJ White The Lancet 403 (10444), 2590-2591, 2024 | | 2024 |
| Rectal artesunate: lives not saved NJ White, T Peto, JA Watson Transactions of The Royal Society of Tropical Medicine and Hygiene, trae036, 2024 | | 2024 |
| Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants T Wattanakul, ME Gilder, R McGready, W Hanpithakpong, NPJ Day, ... Nature Communications 15 (1), 3851, 2024 | | 2024 |
| Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar AM Thu, AP Phyo, C Pateekhum, JD Rae, J Landier, DM Parker, ... Malaria Journal 23 (1), 138, 2024 | | 2024 |
| Comparison of lumefantrine, mefloquine, and piperaquine concentrations between capillary plasma and venous plasma samples in pregnant women with uncomplicated falciparum and … M Saito, P Wilaisrisak, M Pimanpanarak, J Viladpai-Nguen, MK Paw, ... Antimicrobial Agents and Chemotherapy 68 (5), e00093-24, 2024 | | 2024 |
| Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised … P Wongnak, WHK Schilling, P Jittamala, S Boyd, V Luvira, T Siripoon, ... The Lancet Infectious Diseases, 2024 | 1 | 2024 |
| Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match M Cokljat, CV Cruz, VI Carrara, K Puttaraska, C Capriglioni, ... BMJ Global Health 9 (4), e014188, 2024 | | 2024 |
| Does acute malnutrition in young children increase the risk of treatment failure following artemisinin-based combination therapy? A WWARN individual patient data meta-analysis K Stepniewska, R Allan, AR Anvikar, TA Anyorigiya, EA Ashley, Q Bassat, ... The Lancet Global Health 12 (4), e631-e640, 2024 | | 2024 |
| Where will rectal artesunate suppositories save lives? JA Watson, TJ Peto, NJ White The Lancet 403 (10432), 1137-1138, 2024 | 1 | 2024 |
| An artesunate pharmacometric model to explain therapeutic responses in falciparum malaria—authors’ response S Saralamba, JA Simpson, NJ White Journal of Antimicrobial Chemotherapy 79 (3), 692-692, 2024 | | 2024 |
| A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease F Reid, D Singh, M Albayaty, R Moate, E Jimenez, MW Sadiq, D Howe, ... Clinical Pharmacology & Therapeutics 115 (3), 565-575, 2024 | 1 | 2024 |
| The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis S Singh, S Boyd, WHK Schilling, JA Watson, M Mukaka, NJ White Journal of Antimicrobial Chemotherapy, dkae045, 2024 | 1 | 2024 |
| Transmission-blocking activity of artesunate, chloroquine and methylene blue on Plasmodium vivax gametocytes V Chaumeau, P Wasisakun, JA Watson, T Oo, S Aryalamloed, MP Sue, ... bioRxiv, 2024.02. 18.580875, 2024 | | 2024 |
| Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis' JA Watson, RJ Commons, J Tarning, JA Simpson, A Llanos Cuentas, ... Elife 13, e91283, 2024 | 1 | 2024 |
| Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers S Pukrittayakamee, P Jittamala, JA Watson, B Hanboonkunupakarn, ... Elife 12, RP87318, 2024 | 2 | 2024 |
| Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis M Rajasekhar, JA Simpson, B Ley, P Edler, CS Chu, T Abreha, GR Awab, ... The Lancet Infectious Diseases, 2024 | 9 | 2024 |
| 'The Trees Saved Me'. NJR White, A Burdick International New York Times, NA-NA, 2024 | | 2024 |
| Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of phase 2 antiviral studies P Wongnak, WHK Schilling, P Jittamala, SHK Boyd, V Luvira, T Siripoon, ... | 2 | 2024 |
| Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial V Luvira, WHK Schilling, P Jittamala, JA Watson, S Boyd, T Siripoon, ... BMC Infectious Diseases 24 (1), 89, 2024 | 6 | 2024 |
